NASDAQ:CTXR - Citius Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.33 -0.04 (-2.92 %)
(As of 11/14/2018 04:00 PM ET)
Previous Close$1.37
Today's Range$1.30 - $1.4432
52-Week Range$1.12 - $5.45
Volume46,241 shs
Average Volume34,326 shs
Market Capitalization$21.54 million
P/E RatioN/A
Dividend YieldN/A
Beta2.48
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok product, which has completed Phase IIb clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido product, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids. It has a collaboration and license agreement with Alpex Pharma S.A. to develop and commercialize orally disintegrating tablet formulations of pharmaceutical products in United States, Canada, and Mexico. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Receive CTXR News and Ratings via Email

Sign-up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CTXR
Previous Symbol
CUSIPN/A
Phone908-967-6677

Debt

Debt-to-Equity RatioN/A
Current Ratio1.29
Quick Ratio1.29

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.66 per share
Price / Book0.50

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-10,380,000.00
Net MarginsN/A
Return on Equity-54.80%
Return on Assets-49.55%

Miscellaneous

Employees7
Outstanding Shares16,200,000
Market Cap$21.54 million
OptionableNot Optionable

Citius Pharmaceuticals (NASDAQ:CTXR) Frequently Asked Questions

What is Citius Pharmaceuticals' stock symbol?

Citius Pharmaceuticals trades on the NASDAQ under the ticker symbol "CTXR."

When did Citius Pharmaceuticals' stock split? How did Citius Pharmaceuticals' stock split work?

Citius Pharmaceuticals's stock reverse split before market open on Friday, June 9th 2017. The 1-15 reverse split was announced on Thursday, June 8th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 8th 2017. An investor that had 100 shares of Citius Pharmaceuticals stock prior to the reverse split would have 7 shares after the split.

How were Citius Pharmaceuticals' earnings last quarter?

Citius Pharmaceuticals Inc (NASDAQ:CTXR) released its earnings results on Tuesday, August, 14th. The company reported ($0.19) EPS for the quarter, beating analysts' consensus estimates of ($0.32) by $0.13. View Citius Pharmaceuticals' Earnings History.

What price target have analysts set for CTXR?

1 brokerages have issued 1-year target prices for Citius Pharmaceuticals' shares. Their forecasts range from $11.00 to $11.00. On average, they anticipate Citius Pharmaceuticals' stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 714.8% from the stock's current price. View Analyst Price Targets for Citius Pharmaceuticals.

What is the consensus analysts' recommendation for Citius Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Citius Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Citius Pharmaceuticals.

Has Citius Pharmaceuticals been receiving favorable news coverage?

Media coverage about CTXR stock has been trending positive recently, according to InfoTrie. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Citius Pharmaceuticals earned a coverage optimism score of 2.6 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near term.

Who are some of Citius Pharmaceuticals' key competitors?

Who are Citius Pharmaceuticals' key executives?

Citius Pharmaceuticals' management team includes the folowing people:
  • Mr. Leonard L. Mazur, Exec. Chairman & Sec. (Age 73)
  • Mr. Myron Z. Holubiak, Pres, CEO & Director (Age 71)
  • Mr. Jaime Bartushak, CFO & Chief Accounting Officer (Age 50)
  • Mr. Gary F. Talarico, Exec. VP of Operations (Age 63)
  • Mr. Andrew Scott, VP of Corp. Devel.

Who are Citius Pharmaceuticals' major shareholders?

Citius Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.36%). Company insiders that own Citius Pharmaceuticals stock include Leonard L Mazur and Myron Z Holubiak. View Institutional Ownership Trends for Citius Pharmaceuticals.

Which institutional investors are buying Citius Pharmaceuticals stock?

CTXR stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Citius Pharmaceuticals stock in the last two years include Leonard L Mazur and Myron Z Holubiak. View Insider Buying and Selling for Citius Pharmaceuticals.

How do I buy shares of Citius Pharmaceuticals?

Shares of CTXR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Citius Pharmaceuticals' stock price today?

One share of CTXR stock can currently be purchased for approximately $1.35.

How big of a company is Citius Pharmaceuticals?

Citius Pharmaceuticals has a market capitalization of $21.54 million. Citius Pharmaceuticals employs 7 workers across the globe.

What is Citius Pharmaceuticals' official website?

The official website for Citius Pharmaceuticals is http://www.citiuspharma.com.

How can I contact Citius Pharmaceuticals?

Citius Pharmaceuticals' mailing address is 11 Commerce Drive First Floor, Cranford NJ, 07016. The company can be reached via phone at 908-967-6677.


MarketBeat Community Rating for Citius Pharmaceuticals (NASDAQ CTXR)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  76 (Vote Outperform)
Underperform Votes:  84 (Vote Underperform)
Total Votes:  160
MarketBeat's community ratings are surveys of what our community members think about Citius Pharmaceuticals and other stocks. Vote "Outperform" if you believe CTXR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTXR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/14/2018 by MarketBeat.com Staff

Featured Article: Capital Gains

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel